SI-BONE
Develops and commercializes minimally invasive sacroiliac (SI) joint fusion implants, including the 3D-printed iFuse 3D implant, to address SI joint dysfunction and related sacropelvic disorders.
- CEO / Founder
- Laura A. Francis
- Team Size
- 201-500
- Stage
- Public
- Total Funding
- $81.1M
- Latest Round
- IPO
- Key Investors
- Skyline Ventures
Technology & Products
Key Products
iFuse Implant System; iFuse 3D Implant; iFuse TORQ Implant System
Technological Advantage
SI-BONE's iFuse 3D implant leverages additive manufacturing to create a porous surface that enhances bone integration, a key differentiator in orthopedic implants. The company holds 34 U.S. patents (as of June 2018) protecting its implant designs and surgical methods. The technology is protected by patents and regulatory clearances, making it difficult for competitors to replicate directly.
Differentiation
Value Proposition
Provides a minimally invasive surgical solution for SI joint dysfunction, reducing recovery time and improving patient outcomes compared to traditional fusion surgery, with the iFuse 3D implant's porous structure designed to enhance bone integration.
How They Differentiate
SI-BONE is the pioneer and market leader in minimally invasive SI joint fusion, with a dedicated focus on this niche. Its iFuse 3D implant is one of the first 3D-printed titanium implants cleared by the FDA for this indication, offering a unique porous structure for bone integration compared to competitors' solid implants.
Market & Competition
Target Customers
Hospitals, ambulatory surgery centers, and surgeons treating SI joint dysfunction
Industry Verticals
Medical Devices; Orthopedics
Competitors
Globus Medical; Medtronic; SIGNUS Medizintechnik
Growth & Milestones
Growth Metrics
Worldwide revenue of $56.3 million in Q4 2025; 2026 revenue guidance of $228.5 million; Q2 2026 revenue of $56M with 15% growth; U.S. procedure volume growth of 22%.
Major Milestones
2018: IPO on NASDAQ; 2019: Partnership with PrinterPrezz for 3D-printed implants; 2025: Record Q4 financial results
Notable Customers
Hospitals; Ambulatory surgery centers; Surgeons